Fundraising FoxViking Global Investors — 2024 Investments
6 investments dated 2024 · listed companies and verified rows first · show all
Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.
BiotechChapel Hill, US
Robin Walker(Executive Officer)inChristopher Courts(Executive Officer)inJorge Bartolome(Founder)in
BoardBenjamin Gomez(Director)Adam Koppel(Director)inMichael E. Bozik(Director)
Co-investorsARCH Venture PartnersBain Capital Life SciencesGV (Google Ventures)Solas BioVenturesViking GlobalAccess Biotechnology+3 more
Biotech company developing antibodies to treat autoimmune and inflammatory diseases.
Co-investorsAlpha Wave GlobalArkin CapitalArkin Digital HealthJeito CapitalMonograph Capital PartnersViking Global+1 more
Mainstay provides an AI-powered platform that enables higher education institutions to engage students through proactive, personalized coaching and messaging.
AI & Machine LearningEdTechHR TechSaaSArlington, US
Andrew Magliozzi(Founder)inKirk Daulerio(Co-Founder, Vice President, Community)in
BoardKEVIN TALBOT(Director)
Co-investorsAlumni VenturesBisk VenturesEastward Capital PartnersFundersClubK Street CapitalMichelson 20MM Foundation+12 more
Irish company developing an advanced neurostimulation device.
HealthtechPlymouth, US
Dan Sachs(Director)Peter Crosby(Executive Officer, Director)inJason Hannonin
BoardManus Rogan(Director)inAntoine Papiernik(Director)in
Co-investorsFountain Healthcare PartnersIreland Strategic Investment FundSeventure PartnersSofinnova PartnersViking GlobalAlly Bridge Group+1 more
Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.
BiotechDigital HealthHealthtech
Vishal Patelin
Co-investorsAscenta CapitalAtlas VentureBorealis VenturesBorealis VenturesMagnetic VenturesOrbiMed+4 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.